血糖降低方法在糖尿病中的比较效果研究(GRADE):死亡率分析
GRADE研究在2型糖尿病病程10年内、无近期心血管事件或癌症史的人群中评估平均5年随访的死亡率与死因,死亡率为0.59/100人年,最常见死因为心血管复合死因(38.6%)和癌症(26.8%),各治疗组间无差异。
要点
- 平均随访5年,死亡率较低,为0.59/100人年。
- 最常见死因为心血管复合死因(38.6%)和癌症(26.8%)。
- 各治疗组间死亡率无差异。
核心结论
- 在病程相对较短的2型糖尿病患者中,死因呈多样化,各治疗组间死亡率无差异,作者认为需要关注心血管疾病以外的健康风险。
研究设计与样本
- GRADE研究纳入诊断为2型糖尿病10年内且无近期心血管事件或癌症史的人群,评估平均5年随访期间的总死亡率与主要死因,死因由设盲委员会集中裁定。
主要发现
- 死亡率为0.59/100人年。
- 随访期间死亡者更可能年龄较大、男性、有高血压史、有吸烟史以及有中度白蛋白尿。
- 最常见的两个根本死因为「心血管死因」(复合根本死因)占38.6%和癌症占26.8%。
- 各治疗组间无差异。
临床怎么用
- 原文结论指出,在病程相对较短的糖尿病患者中死因呈多样化,关注心血管疾病以外的健康风险是有必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We report mortality outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) among people with type 2 diabetes diagnosed within 10 years and no recent history of cardiovascular events or cancer. RESEARCH DESIGN AND METHODS: Overall mortality rates and major causes of death were assessed over an average of 5 years of follow-up. Cause of death was adjudicated centrally by a committee masked to treatment assignment. We examined baseline covariates and the 10-year Framingham Risk Score for associations. RESULTS: Mortality rate was low (0.59 per 100 participant-years). Participants who died during follow-up were likely to be older, be male, have a history of hypertension, have a history of smoking, and have moderate albuminuria. The two most common underlying causes of death were "cardiovascular-cause" (a composite of underlying causes) (38.6%) and cancer (26.8%). There were no differences by treatment group. CONCLUSIONS: Among people with diabetes of relatively short duration, cause of death was varied. Attention to health risks beyond cardiovascular diseases is warranted.
引用
- Banerji MA, Buse JB, Younes N, et al. Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 38252886. doi:10.2337/dc23-1356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。